<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15859443</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-3006</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Anesthesia progress</Title><ISOAbbreviation>Anesth Prog</ISOAbbreviation></Journal><ArticleTitle>Continuous infusion propofol general anesthesia for dental treatment in patients with progressive muscular dystrophy.</ArticleTitle><Pagination><StartPage>12</StartPage><EndPage>16</EndPage><MedlinePgn>12-6</MedlinePgn></Pagination><Abstract><AbstractText>Progressive muscular dystrophy may produce abnormal reactions to several drugs. There is no consensus of opinion regarding the continuous infusion of propofol in patients with progressive muscular dystrophy. We successfully treated 2 patients with progressive muscular dystrophy who were anesthetized with a continuous infusion of propofol. In case 1, a 19-year-old, 59-kg man with Becker muscular dystrophy and mental retardation was scheduled for dental treatment under general anesthesia. General anesthesia was maintained by a continuous infusion of 6-10 mg/kg propofol per hour and an inhalational mixture of 67% nitrous oxide and 33% oxygen. No complications were observed during or after the operation. In case 2, a 5-year-old, 11-kg boy with Fukuyama type congenital muscular dystrophy and slight mental retardation was scheduled for dental treatment under general anesthesia. General anesthesia was maintained with a continuous infusion of 6-12 mg/kg propofol per hour and an inhalational mixture of 0.5-1.5% sevoflurane in 67% nitrous oxide and 33% oxygen. No complications were observed during or after the operation. It is speculated that a continuous infusion of propofol in progressive muscular dystrophy does not cause malignant hyperthermia because serum levels of creatine phosphokinase and myoglobin decreased after our anesthetic management. Furthermore, our observations suggest that sevoflurane may have some advantages in patients with progressive type muscular dystrophies other than Duchenne muscular dystrophy and Becker muscular dystrophy. In conclusion, our cases suggest that a continuous infusion of propofol for the patients with progressive muscular dystrophy is a safe component of our anesthetic strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawaai</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dental Anesthesiology, Ohu University School of Dentistry, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Kazuho</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesth Prog</MedlineTA><NlmUniqueID>0043533</NlmUniqueID><ISSNLinking>0003-3006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009211">Myoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI7VU623SF</RegistryNumber><NameOfSubstance UI="D015742">Propofol</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000766" MajorTopicYN="Y">Anesthesia, Dental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000771" MajorTopicYN="Y">Anesthesia, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018685" MajorTopicYN="N">Anesthetics, Inhalation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017742" MajorTopicYN="Y">Dental Care for Chronically Ill</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008305" MajorTopicYN="N">Malignant Hyperthermia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009136" MajorTopicYN="N">Muscular Dystrophies</DescriptorName><QualifierName UI="Q000151" MajorTopicYN="N">congenital</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="N">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009211" MajorTopicYN="N">Myoglobin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015742" MajorTopicYN="N">Propofol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15859443</ArticleId><ArticleId IdType="pmc">PMC2526213</ArticleId><ArticleId IdType="doi">10.2344/0003-3006(2005)52[12:CIPGAF]2.0.CO;2</ArticleId><ArticleId IdType="sici">i0003-3006-52-1-12</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palmucci L, Doriguzzi C, Mongini T, et al. Dilating cardiomyopathy as the expression of Xp21 Becker type muscular dystrophy. J Neurol Sci. 1992;111:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1431989</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito M, Kawai H, Akaike M, Adachi K, Nashida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J. 1996;132:642&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">8800037</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama Y, Kawazura M, Haruna H. A peculiar form of congenital progressive muscular dystrophy. Paediatr Univ Tokyo. 1960;4:5&#x2013;8.</Citation></Reference><Reference><Citation>Terasawa K. Muscle regeneration and satellite cells in Fukuyama type congenital muscular dystrophy. Muscle Nerve. 1986;9:465&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">3724791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsburg RS, Porterfield K, Lippmann M. Propofol: bolus induction plus continuous infusion in a patient with Duchenne muscular dystrophy. Anesthesiology. 1991;75:376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1859027</ArticleId></ArticleIdList></Reference><Reference><Citation>Egi M, Tokioka H, Chikai T, et al. Propofol anesthesia for a patient with progressive muscular dystrophy. Masui. 2002;51:196&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">11889793</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfield MC. Increased propofol requirements in a child with Duchenne muscular dystrophy. Anaesthesia. 1993;48:1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8250172</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin MG, Henderson M. Cardiac arrest during major spinal scoliosis surgery in a patient with Duchenne's muscular dystrophy undergoing intravenous anaesthesia. Anaesth Intensive Care. 1995;23:626&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787270</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomosa H, Nakahashi K, Hayashi M, Marunaka S, Yan S, Hiraki N. General anesthesia with sevoflurane and vecuronium for patients with dystrophia myotonica and progressive muscular dystrophy. Masui. 1991;4:1730&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">1685000</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda Y, Hayashi M, Obara H. Sevoflurane anesthesia for a patient with facioscapulohumera muscle dystrophy. Masui. 1994;43:580&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">8189626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossu F, Caboni MT. Propofol in Duchenne muscular dystrophy. Minerva Anesthesiol. 1995;61:51&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7617241</ArticleId></ArticleIdList></Reference><Reference><Citation>Obata R, Yasumi Y, Suzuki A, Nakajima Y, Sato S. Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth. 1999;46:564&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391604</ArticleId></ArticleIdList></Reference><Reference><Citation>Capozzoli G, Auricchio F, Accinelli G. Total intravenous anaesthesia without muscle relaxants in a child with diagnosed Duchenne muscular dystrophy. Minerva Anesthesiol. 2000;66:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">11213553</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Shimokawa M, Sha K, et al. Sevoflurane can induce rhabdomylolysis in Duchenne's muscular dystrophy. Masui. 2002;51:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11889791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerald V, Robin G. Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth. 1999;46:525&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391598</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkiadis GA, Branch KG. Cardiac arrest after isoflurane anaesthesia in a patient with Duchenne's muscular dystrophy. Anaesthesia. 1990;45:22&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2316833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethna NF, Rockhoff MA. Cardiac arrest following inhalation induction of anaesthesia in child with Duchenne's muscular dystrophy. Can Anaesth Soc J. 1986;33:799&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">3779502</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge LM. Anaesthetic problems in myotonic dystrophy. Br J Anaesth. 1985;57:1119&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">4052304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda Y, Okamoto T, Satoh T. General anesthesia conducted twice in myotonic dystrophy. Masui. 1993;42:742&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">8099979</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Danielson A. Sevoflurane-based anesthesia in a patient with myotonia dystrophica. Anesth Analg. 1996;83:442.</Citation><ArticleIdList><ArticleId IdType="pubmed">8694352</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirly PJ, McFarlane H. Sevoflurane for oesophagos-copy in a patient with myotonic dystrophy. Can J Anaesth. 1998;45:821&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">9793677</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks LF, Edwards JC, Linter SPK. Propofol during cardiopulmonary bypasss in a patient susceptible to malignant hyperpyrexia. Anaesth Intensive Care. 1988;16:482&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">3266064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fruen BR, Michelson JR, Roghair TJ, Litterer LA, Louis CF. Effects of propofol on Ca2+ regulation by malignant hyperthermia&#x2014;susceptible muscle membranes. Anesthesiology. 1995;82:1274&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">7741303</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xf6;tz FB, Waalkens HJ, Verkade HJ, Strengers JLM, Knoester H, Mandera JM. Fatal side effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care. 1996;24:724.</Citation><ArticleIdList><ArticleId IdType="pubmed">8971326</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff SPW, Futter ME, Anderson BJ. Fatal outcome after propofol sedation in children. Anaesth Intensive Care. 1997;25:581&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">9352777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock AN, McKenzie AJ, Hodges M. Propofol and malignant hyperthermia susceptibility. Anaesth Intensive Care. 1997;25:583&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">9352778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>